While lower expression of MGMT is desired in glioma cells for better TMZ efficacy, successful immune response in MG patients depends upon the functional efficiency of MGMT in conferring resistance to TMZ cytotoxicity. The gene discussed is MGMT; the disease is myasthenia gravis.